← Insulet overview

Insulet vs DexCom: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Insulet Corporation (PODD)

Q3 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

July 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

Latest
▼3

Insulet's U.S. Type 2 Weakness and Legal Woes Weigh on Outlook

  • Securities fraud class action expands with multiple law firm filings Several law firms filed or reminded investors of a securities fraud class action alleging Insulet misled about Omnipod safety and manufacturing. The August 31 lead plaintiff deadline keeps legal risk in focus, which can pressure the stock as investors weigh potential costs and reputational damage.

    This is a new legal development that adds to regulatory risk and could hurt investor confidence.

  • Insulet cuts 2026 revenue growth guidance on weak U.S. Type 2 retention Insulet lowered its 2026 revenue growth outlook to 20-22% from a prior forecast, citing lower-than-expected use and retention among U.S. Type 2 diabetes customers. Although Q2 revenue beat estimates, the reduced guidance signals weaker future demand, which pushes the stock down.

    This is a new guidance cut that directly reduces expected future revenue and earnings.

  • JPMorgan downgrades Insulet to Neutral, slashes price target to $152 JPMorgan downgraded Insulet to Neutral from Overweight and cut its price target to $152 from $275, citing slowing U.S. growth, rising Type 2 attrition, and competition. The downgrade reflects a more cautious view on 2027, which can lead to selling pressure and lower valuation.

    This is a new analyst downgrade that directly impacts investor sentiment and valuation.

▼2▲1

Insulet's strong sales offset by FDA Class I recall and fraud lawsuit

  • Next-gen Omnipod 6 shows strong trial results Insulet reported positive clinical trial results for its next-generation Omnipod 6 automated insulin delivery system and a fully closed-loop system for type 2 diabetes. The trial showed up to 50% more automated insulin delivery and fewer manual boluses. This innovation could drive future demand and support long-term growth, pushing the stock up.

    New product pipeline news that could boost future revenue and investor confidence.

  • FDA Class I recall of Omnipod devices The FDA classified a recall of certain Omnipod 5, DASH, and Eros insulin pumps as Class I, the most serious type, due to a cannula tear that can cause insulin leakage and under-delivery. This raises safety concerns, may lead to regulatory scrutiny, and could hurt sales and reputation, pushing the stock down.

    A major regulatory setback that directly threatens patient safety and future revenue.

  • Securities fraud class action lawsuit filed A securities fraud class action lawsuit alleges Insulet misled investors about product safety and manufacturing quality. The lawsuit follows two product corrections in 2026 that caused stock drops. Legal costs and potential damages could weigh on the stock, and the lawsuit may keep investors cautious.

    New legal risk that could result in financial penalties and further erode investor trust.

  • Strong Omnipod 5 momentum vs. competition and macro headwinds Omnipod 5 continues to grow rapidly, with 33% revenue growth and a 25% larger customer base. However, intensifying competition and higher raw material and shipping costs from the Middle East conflict could limit profit margins. The strong demand supports the stock, but these headwinds may cap gains.

    Balances the positive sales momentum against real pressures that could affect profitability.

DexCom Inc (DXCM)

Q3 2026
▲3▼1

DexCom gains on FDA clearance, strong Q2, and expanded coverage

  • FDA clears Stelo for young children The FDA cleared DexCom's Stelo biosensor for children aged 2 and up, opening a new market and supporting the stock.

    This is a new regulatory win that expands the addressable market.

  • Q2 revenue up 13%, guidance raised Q2 revenue rose 13% to $1.31 billion, leading DexCom to raise its 2026 revenue and margin guidance, a sign of strong business momentum.

    This is a new financial update that directly boosts investor confidence.

  • Investor Day and G7 rollout lift shares DexCom's Investor Day sent shares up 25%, and the G7 15 Day rollout progressed, with major PBM coverage now reaching over 7 million non-insulin Type 2 patients.

    These are new events that drove the stock higher during the quarter.

  • Abbott competition intensifies Abbott's FreeStyle Libre topped $2 billion in Q2 sales, and the FDA approved Abbott's Libre Duo, the first U.S. wearable tracking both glucose and ketones, potentially pressuring DexCom's pricing and market share.

    This is a new competitive threat that could weigh on DexCom's future growth.

August 2026
▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

  • Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.

    This is the core fundamental news that explains the stock's recent strength and improved outlook.

  • G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.

    It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.

  • Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.

    It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.

  • Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.

    It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

Latest
▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

  • Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.

    This is the core fundamental news that explains the stock's recent strength and improved outlook.

  • G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.

    It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.

  • Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.

    It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.

  • Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.

    It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

July 2026
▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

  • FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.

    This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.

  • DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.

    This is a fresh earnings report with raised guidance, a major positive driver for the stock.

  • Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.

    This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.

  • Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.

    This explains a major positive sentiment shift and is a new event that boosted the stock.

▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

  • FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.

    This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.

  • DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.

    This is a fresh earnings report with raised guidance, a major positive driver for the stock.

  • Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.

    This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.

  • Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.

    This explains a major positive sentiment shift and is a new event that boosted the stock.

© 2026 MarketDXWhy